Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Elizabeth B Lamont, MD MS, MMSc, Andrew J. Yee, MD, Stuart L. Goldberg, MD, Andrew D Norden, MD MPH, MBA

Blood (2019) 134 (Supplement_1): 2193.

https://doi.org/10.1182/blood-2019-125407

Published: 2019

Journal Articles

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Stuart L. Goldberg, MD, Michael J. Mauro, MD

Blood (2019) 134 (Supplement_1): 2929.

https://doi.org/10.1182/blood-2019-127959

Published: 2019

Journal Articles

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Stuart L. Goldberg, MD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Scott Justin Keating, MSc, BSc, Hitesh Bhandari, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 4151.

https://doi.org/10.1182/blood-2019-128290

Published: 2019

Journal Articles

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sudarsan Kollimuttathuliam, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Stuart L. Goldberg, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 4576.

https://doi.org/10.1182/blood-2019-132052

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Sarah S. Makhani, BA, Ronit Reich-Slotky, PhD, Pashna N. Munshi, MD, Noa Biran, MD, Michele L. Donato, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, David S. Siegel, David H. Vesole, MD PhD, Scott D. Rowley, MD

Blood (2019) 134 (Supplement_1): 4475.

https://doi.org/10.1182/blood-2019-122111

Published: 2019

Journal Articles

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Marshall McKenna, MD, Rena Feinman, PhD, Jaeil Ahn, PhD, Shuqi Wang, MSc, Elli Gourna Paleoudis, PhD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Jun Chih Wang, MD, Abdul Rehman, MD, Giselle Alexandra Suero-Abreu, MD PhD, Phyllis McKiernan, Michele L. Donato, MD, Scott D. Rowley, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 5510.

https://doi.org/10.1182/blood-2019-132134

Published: 2019

Journal Articles

The Unforeseen Medical and Business Challenges Found When Integrating Abstracted Data from Disparate EHR Systems While Building the Curecloud Direct-to-Patient Multiple Myeloma Registry

Steven E. Labkoff, MD, Shaadi Mehr, PhD, Christopher Williams, Daniel Auclair, Paul A. Giusti, MBA, Kathy E. Giusti, MBA, Stuart L. Goldberg, MD, Kevin M Keogh, Andrew J. Belli, MPH, Andrew D Norden, MDMPH MBA

Blood (2019) 134 (Supplement_1): 4736.

https://doi.org/10.1182/blood-2019-130276

Published: 2019

Journal Articles

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Marshall McKenna, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 3316.

https://doi.org/10.1182/blood-2019-132114

Published: 2019

Journal Articles

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Nikhita Gadi, MDMSc, Linda Schmidt, RN, Jaeil Ahn, PhD, Tianmin Wu, MS, Scott D. Rowley, MD, Elli Gourna Paleoudis, PhD, Michele L. Donato, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 3141.

https://doi.org/10.1182/blood-2019-129504

Published: 2019

Journal Articles

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Blood (2018) 132 (Supplement 1): 4452.

https://doi.org/10.1182/blood-2018-99-115971

Published: 2018

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Multiple Myeloma Staging in Real World Clinical Practice Is Suboptimal: Absence of Beta-2-Microglobulin and Serum Lactase Dehydrogenase Testing Are Limiting Factors

Noa Biran, MD, Sukhmani Gill, MD, Andrew D Norden, MD MPH MBA, David H. Vesole, MD PhD, Wallace G Stephen, MD, Kenneth D Nahum, DO, David S Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2018) 132 (Supplement 1): 5587.

https://doi.org/10.1182/blood-2018-99-119559

Published: 2018

Journal Articles

The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients

Artur Jurczyszyn, MD, Sarah Goldman-Mazur, MD, Jorge J. Castillo, MD, Anna Waszczuk-Gajda, Norbert Grząśko, MD PhD, Max Bittrich, MD, Andrew J Yee, MD, Anna Suska, MD, Deepu Madduri, MD, Saurabh Chhabra, MD, Ariel Kleman, MD, Parameswaran Hari, MBBS, MD, Stuart L. Goldberg, MD, Aimee Chappell, Massimo Gentile, David H. Vesole, MD PhD

Blood (2018) 132 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2018-99-115816

Published: 2018

Journal Articles

FISH Abnormalities (including R-ISS defining and IgH mutations) Are Similar across Race and Ethnicity Among Patients with Multiple Myeloma (except higher rates of t(4:14) in Minorities and 1q Amplifications in Asian/Indians)

Noa Biran, MD, Camille Johnson, MD, Andrew D Norden, MD MPH MBA, Roger Kumar, BS MS, David H. Vesole, MD PhD, Seth H. Berk, MD, Denis B. Fitzgerald, MD, David S Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2018) 132 (Supplement 1): 5608.

https://doi.org/10.1182/blood-2018-99-119744

Published: 2018

Journal Articles

Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Michael J. Mauro, MD, Ginny P Sen, MPH, Srikanth Gajavelli, MD, Catherine Davis, PharmD, Stuart L. Goldberg, MD

Blood (2018) 132 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2018-99-118119

Published: 2018

Journal Articles

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Joshua R Richter, MD, Noa Biran, MD, Dhakshila Paramanathan, Srikesh Arunajadai, PhD, Victoria DeVincenzo, Ruth Pe Benito, Brooke Gruman, Sukhi Kaur, John Hervey, Eric Schultz, Scott Paddock, Andrew L. Pecora, MD, David H. Vesole, MD, David Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2017) 130 (Supplement 1): 679.

https://doi.org/10.1182/blood.V130.Suppl_1.679.679

Published: 2017

Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Blood (2017) 130 (Supplement 1): 891.

https://doi.org/10.1182/blood.V130.Suppl_1.891.891

Published: 2017

Journal Articles

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Lori A. Leslie, MD, Sejal Kothadia, MD, Ewelina Protomastro, MS, Patricia J Greenberg, Tracy Andrews, PhD, Ann McNeill, ANP, Hoshiyuki Iida, Alan P Skarbnik, MD, Xiao Yang, Pritish K. Bhattacharyya, MD, Kar Fai Chow, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, Tatyana A Feldman, MD, Andre Goy, MD

Blood (2017) 130 (Supplement 1): 4163.

https://doi.org/10.1182/blood.V130.Suppl_1.4163.4163

Published: 2017

Journal Articles

Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Stuart L. Goldberg, MD, Mauricette Michallet, MD PhD, Rüdiger Hehlmann, MD, Bengt Simonsson, MD, Michael J. Mauro, MD, Loretta A. Williams, PhD MSN, BSN, BA, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Ginny P Sen, MPH, Aimee Foreman, MA, Srikanth Gajavelli, MD, Carlo Gambacorti-Passerini, MD

Blood (2017) 130 (Supplement 1): 2894.

https://doi.org/10.1182/blood.V130.Suppl_1.2894.2894

Published: 2017

NARROW

Chromosome 1q Amplification Is Associated with a History of Prior Malignancies Among Patients Newly Diagnosed with Multiple Myeloma

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

The Unforeseen Medical and Business Challenges Found When Integrating Abstracted Data from Disparate EHR Systems While Building the Curecloud Direct-to-Patient Multiple Myeloma Registry

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Multiple Myeloma Staging in Real World Clinical Practice Is Suboptimal: Absence of Beta-2-Microglobulin and Serum Lactase Dehydrogenase Testing Are Limiting Factors

The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients

FISH Abnormalities (including R-ISS defining and IgH mutations) Are Similar across Race and Ethnicity Among Patients with Multiple Myeloma (except higher rates of t(4:14) in Minorities and 1q Amplifications in Asian/Indians)

Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL

Cytogenetic and Molecular Responses after 2 Years of Tyrosine Kinase Inhibitor (TKI) Treatment in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only